Alcohol septal ablation or mavacamten for obstructive hypertrophic cardiomyopathy

  • Hypertrophic cardiomyopathy (HCM) is a genetic disease characterized by an increased left ventricular wall thickness in the absence of increased afterload conditions. In addition to diastolic dysfunction, obstruction of the left ventricular outflow tract is common in HCM and has an important influence on symptoms and outcome. Over the last five decades or two decades, respectively, surgical myectomy and alcohol septal ablation were the only therapeutic options if standard medical care was not sufficient. Recently, a new option has become available that has the potential to revolutionize the therapeutic strategies for patients with HCM. Mavacamten is a myosin inhibitor that belongs to a completely new drug class and targets the excessive actin–myosin cross-bridging that is the underlying pathology of HCM. By reducing the actin–myosin interactions, mavacamten not only reduces the left ventricular outflow tract (LVOT) obstruction but also seems to have positive effects on the diastolic function, microcirculation, and cardiac structure. This article summarizes the current evidence on alcohol septal ablation and reviews the preclinical and clinical data on mavacamten for the treatment of patients with obstructive HCM.

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar
Author:Smita ScholtzGND, Volker RudolphORCiDGND, Jan-Christian ReilORCiDGND
Parent Title (English):Journal of clinical medicine
Place of publication:Basel
Document Type:Article
Date of Publication (online):2024/03/20
Date of first Publication:2023/10/19
Publishing Institution:Ruhr-Universität Bochum, Universitätsbibliothek
Tag:Open Access Fonds
alcohol septal ablation; hypertrophic cardiomyopathy; left ventricular outflow tract obstruction; mavacamten; myosin inhibitor; septal reduction therapy
Issue:20, Artikel 6628
First Page:6628-1
Last Page:6628-17
Article Processing Charge funded by the Deutsche Forschungsgemeinschaft (DFG) and the Open Access Publication Fund of Ruhr-Universität Bochum.
Institutes/Facilities:Herz- und Diabeteszentrum NRW, Klinik für Allgemeine und Interventionelle Kardiologie / Angiologie
Dewey Decimal Classification:Technik, Medizin, angewandte Wissenschaften / Medizin, Gesundheit
open_access (DINI-Set):open_access
Licence (English):License LogoCreative Commons - CC BY 4.0 - Attribution 4.0 International